Error message
Plaque Psoriasis
Plaque Psoriasis Is Associated With a Substantial Economic Burden on Healthcare Systems
A systematic review of selected peer-reviewed articles (N=91) examined the clinical, economic, and/or social burdens of psoriasis in the United States.
In the study, patients with psoriasis had higher annual total healthcare costs per patient ($22,713 vs $4993; adjusted cost difference [ACD] $18,960; P<.001) than the control group.
Patients with moderate-to-severe disease incurred significantly higher all-cause healthcare costs compared with control patients
Costs substantially increase with comorbid conditions, such as heart disease, hyperlipidemia, hypertension, diabetes, and lung disease.
Comorbidities also include psychiatric conditions, including social stigmatization, depression, and suicide.
Costs were led by significantly higher all-cause medication costs ($14,698 vs $1101; ACD $13,990; P<.001).
Biologic therapies are largely responsible for the pharmacy costs. However, approval of biosimilar products is expected to ease the cost burden.